nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—CYP3A5—Docetaxel—head and neck cancer	0.172	0.303	CbGbCtD
Rivaroxaban—ABCB1—Vinblastine—head and neck cancer	0.136	0.239	CbGbCtD
Rivaroxaban—ABCB1—Docetaxel—head and neck cancer	0.112	0.197	CbGbCtD
Rivaroxaban—CYP3A4—Vinblastine—head and neck cancer	0.0816	0.143	CbGbCtD
Rivaroxaban—CYP3A4—Docetaxel—head and neck cancer	0.0673	0.118	CbGbCtD
Rivaroxaban—Blister—Hydroxyurea—head and neck cancer	0.0106	0.0265	CcSEcCtD
Rivaroxaban—Rectal haemorrhage—Vinblastine—head and neck cancer	0.00928	0.0232	CcSEcCtD
Rivaroxaban—Blister—Fluorouracil—head and neck cancer	0.00763	0.019	CcSEcCtD
Rivaroxaban—Blood urea increased—Hydroxyurea—head and neck cancer	0.00722	0.018	CcSEcCtD
Rivaroxaban—Myocardial ischaemia—Fluorouracil—head and neck cancer	0.00685	0.0171	CcSEcCtD
Rivaroxaban—Renal failure acute—Hydroxyurea—head and neck cancer	0.00601	0.015	CcSEcCtD
Rivaroxaban—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.00581	0.0145	CcSEcCtD
Rivaroxaban—Dermatitis atopic—Docetaxel—head and neck cancer	0.00537	0.0134	CcSEcCtD
Rivaroxaban—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.0052	0.013	CcSEcCtD
Rivaroxaban—Angina pectoris—Vinblastine—head and neck cancer	0.00512	0.0128	CcSEcCtD
Rivaroxaban—Myocardial ischaemia—Docetaxel—head and neck cancer	0.00494	0.0123	CcSEcCtD
Rivaroxaban—CYP2J2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.00467	0.158	CbGpPWpGaD
Rivaroxaban—Swelling—Fluorouracil—head and neck cancer	0.00453	0.0113	CcSEcCtD
Rivaroxaban—Agranulocytosis—Vinblastine—head and neck cancer	0.00438	0.0109	CcSEcCtD
Rivaroxaban—Oropharyngeal pain—Docetaxel—head and neck cancer	0.00437	0.0109	CcSEcCtD
Rivaroxaban—Infestation NOS—Hydroxyurea—head and neck cancer	0.00428	0.0107	CcSEcCtD
Rivaroxaban—Infestation—Hydroxyurea—head and neck cancer	0.00428	0.0107	CcSEcCtD
Rivaroxaban—Haemoglobin—Vinblastine—head and neck cancer	0.00423	0.0106	CcSEcCtD
Rivaroxaban—Haemorrhage—Vinblastine—head and neck cancer	0.00421	0.0105	CcSEcCtD
Rivaroxaban—Blood bilirubin increased—Docetaxel—head and neck cancer	0.0042	0.0105	CcSEcCtD
Rivaroxaban—Dermatitis bullous—Fluorouracil—head and neck cancer	0.00418	0.0104	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00404	0.0101	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.00399	0.00997	CcSEcCtD
Rivaroxaban—Osteoarthritis—Fluorouracil—head and neck cancer	0.00399	0.00997	CcSEcCtD
Rivaroxaban—Haemoglobin—Hydroxyurea—head and neck cancer	0.00386	0.00963	CcSEcCtD
Rivaroxaban—Haemorrhage—Hydroxyurea—head and neck cancer	0.00384	0.00958	CcSEcCtD
Rivaroxaban—Angiopathy—Hydroxyurea—head and neck cancer	0.00348	0.00869	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Vinblastine—head and neck cancer	0.0034	0.00848	CcSEcCtD
Rivaroxaban—Anaemia—Vinblastine—head and neck cancer	0.00339	0.00845	CcSEcCtD
Rivaroxaban—Angina pectoris—Fluorouracil—head and neck cancer	0.00336	0.00839	CcSEcCtD
Rivaroxaban—Malaise—Vinblastine—head and neck cancer	0.0033	0.00825	CcSEcCtD
Rivaroxaban—Swelling—Docetaxel—head and neck cancer	0.00327	0.00815	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.0031	0.00774	CcSEcCtD
Rivaroxaban—Anaemia—Hydroxyurea—head and neck cancer	0.00309	0.00771	CcSEcCtD
Rivaroxaban—Discomfort—Vinblastine—head and neck cancer	0.00308	0.00769	CcSEcCtD
Rivaroxaban—Infestation NOS—Fluorouracil—head and neck cancer	0.00308	0.00768	CcSEcCtD
Rivaroxaban—Infestation—Fluorouracil—head and neck cancer	0.00308	0.00768	CcSEcCtD
Rivaroxaban—Dermatitis bullous—Docetaxel—head and neck cancer	0.00302	0.00753	CcSEcCtD
Rivaroxaban—Malaise—Hydroxyurea—head and neck cancer	0.00301	0.00752	CcSEcCtD
Rivaroxaban—Urinary tract infection—Fluorouracil—head and neck cancer	0.00299	0.00747	CcSEcCtD
Rivaroxaban—Epistaxis—Fluorouracil—head and neck cancer	0.0029	0.00724	CcSEcCtD
Rivaroxaban—Sinusitis—Fluorouracil—head and neck cancer	0.00289	0.00721	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.00288	0.00719	CcSEcCtD
Rivaroxaban—Pain in extremity—Docetaxel—head and neck cancer	0.00288	0.00719	CcSEcCtD
Rivaroxaban—Agranulocytosis—Fluorouracil—head and neck cancer	0.00287	0.00717	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00283	0.00705	CcSEcCtD
Rivaroxaban—Discomfort—Hydroxyurea—head and neck cancer	0.00281	0.00701	CcSEcCtD
Rivaroxaban—Haemoglobin—Fluorouracil—head and neck cancer	0.00278	0.00693	CcSEcCtD
Rivaroxaban—Haemorrhage—Fluorouracil—head and neck cancer	0.00276	0.0069	CcSEcCtD
Rivaroxaban—Oedema—Hydroxyurea—head and neck cancer	0.00273	0.00681	CcSEcCtD
Rivaroxaban—Infection—Hydroxyurea—head and neck cancer	0.00271	0.00676	CcSEcCtD
Rivaroxaban—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00267	0.00667	CcSEcCtD
Rivaroxaban—Skin disorder—Hydroxyurea—head and neck cancer	0.00265	0.00661	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Docetaxel—head and neck cancer	0.00263	0.00657	CcSEcCtD
Rivaroxaban—Constipation—Vinblastine—head and neck cancer	0.00256	0.00638	CcSEcCtD
Rivaroxaban—Pain—Vinblastine—head and neck cancer	0.00256	0.00638	CcSEcCtD
Rivaroxaban—Feeling abnormal—Vinblastine—head and neck cancer	0.00246	0.00615	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00245	0.0061	CcSEcCtD
Rivaroxaban—Dyspnoea—Hydroxyurea—head and neck cancer	0.00243	0.00607	CcSEcCtD
Rivaroxaban—Angina pectoris—Docetaxel—head and neck cancer	0.00243	0.00606	CcSEcCtD
Rivaroxaban—Dyspepsia—Hydroxyurea—head and neck cancer	0.0024	0.00599	CcSEcCtD
Rivaroxaban—Abdominal pain—Vinblastine—head and neck cancer	0.00236	0.0059	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00235	0.00588	CcSEcCtD
Rivaroxaban—Fatigue—Hydroxyurea—head and neck cancer	0.00235	0.00587	CcSEcCtD
Rivaroxaban—Pain—Hydroxyurea—head and neck cancer	0.00233	0.00582	CcSEcCtD
Rivaroxaban—Constipation—Hydroxyurea—head and neck cancer	0.00233	0.00582	CcSEcCtD
Rivaroxaban—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00225	0.00561	CcSEcCtD
Rivaroxaban—CYP2J2—Xenobiotics—CYP1A1—head and neck cancer	0.00224	0.0758	CbGpPWpGaD
Rivaroxaban—Anaemia—Fluorouracil—head and neck cancer	0.00222	0.00555	CcSEcCtD
Rivaroxaban—Infestation—Docetaxel—head and neck cancer	0.00222	0.00554	CcSEcCtD
Rivaroxaban—Infestation NOS—Docetaxel—head and neck cancer	0.00222	0.00554	CcSEcCtD
Rivaroxaban—Hypersensitivity—Vinblastine—head and neck cancer	0.0022	0.0055	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.0022	0.0055	CcSEcCtD
Rivaroxaban—Renal failure—Docetaxel—head and neck cancer	0.00218	0.00545	CcSEcCtD
Rivaroxaban—Jaundice—Docetaxel—head and neck cancer	0.00217	0.0054	CcSEcCtD
Rivaroxaban—Asthenia—Vinblastine—head and neck cancer	0.00215	0.00535	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Docetaxel—head and neck cancer	0.0021	0.00524	CcSEcCtD
Rivaroxaban—Epistaxis—Docetaxel—head and neck cancer	0.0021	0.00523	CcSEcCtD
Rivaroxaban—Agranulocytosis—Docetaxel—head and neck cancer	0.00207	0.00517	CcSEcCtD
Rivaroxaban—Chest pain—Fluorouracil—head and neck cancer	0.00205	0.00511	CcSEcCtD
Rivaroxaban—Diarrhoea—Vinblastine—head and neck cancer	0.00205	0.00511	CcSEcCtD
Rivaroxaban—Discomfort—Fluorouracil—head and neck cancer	0.00202	0.00505	CcSEcCtD
Rivaroxaban—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00201	0.00501	CcSEcCtD
Rivaroxaban—Haemoglobin—Docetaxel—head and neck cancer	0.002	0.005	CcSEcCtD
Rivaroxaban—Haemorrhage—Docetaxel—head and neck cancer	0.00199	0.00498	CcSEcCtD
Rivaroxaban—Hepatitis—Docetaxel—head and neck cancer	0.00199	0.00498	CcSEcCtD
Rivaroxaban—Dizziness—Vinblastine—head and neck cancer	0.00198	0.00493	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Docetaxel—head and neck cancer	0.00197	0.00491	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00196	0.0049	CcSEcCtD
Rivaroxaban—Oedema—Fluorouracil—head and neck cancer	0.00196	0.0049	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Docetaxel—head and neck cancer	0.00196	0.00489	CcSEcCtD
Rivaroxaban—Asthenia—Hydroxyurea—head and neck cancer	0.00196	0.00488	CcSEcCtD
Rivaroxaban—Urethral disorder—Docetaxel—head and neck cancer	0.00195	0.00488	CcSEcCtD
Rivaroxaban—Infection—Fluorouracil—head and neck cancer	0.00195	0.00487	CcSEcCtD
Rivaroxaban—Nervous system disorder—Fluorouracil—head and neck cancer	0.00193	0.0048	CcSEcCtD
Rivaroxaban—Tachycardia—Fluorouracil—head and neck cancer	0.00192	0.00478	CcSEcCtD
Rivaroxaban—Vomiting—Vinblastine—head and neck cancer	0.0019	0.00474	CcSEcCtD
Rivaroxaban—Erythema multiforme—Docetaxel—head and neck cancer	0.00189	0.00471	CcSEcCtD
Rivaroxaban—Headache—Vinblastine—head and neck cancer	0.00187	0.00468	CcSEcCtD
Rivaroxaban—Diarrhoea—Hydroxyurea—head and neck cancer	0.00187	0.00466	CcSEcCtD
Rivaroxaban—Eye disorder—Docetaxel—head and neck cancer	0.00186	0.00465	CcSEcCtD
Rivaroxaban—Cardiac disorder—Docetaxel—head and neck cancer	0.00185	0.00462	CcSEcCtD
Rivaroxaban—Hypotension—Fluorouracil—head and neck cancer	0.00183	0.00458	CcSEcCtD
Rivaroxaban—Angiopathy—Docetaxel—head and neck cancer	0.00181	0.00452	CcSEcCtD
Rivaroxaban—Dizziness—Hydroxyurea—head and neck cancer	0.0018	0.0045	CcSEcCtD
Rivaroxaban—Immune system disorder—Docetaxel—head and neck cancer	0.0018	0.0045	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Docetaxel—head and neck cancer	0.0018	0.00449	CcSEcCtD
Rivaroxaban—Nausea—Vinblastine—head and neck cancer	0.00178	0.00443	CcSEcCtD
Rivaroxaban—Dyspnoea—Fluorouracil—head and neck cancer	0.00175	0.00437	CcSEcCtD
Rivaroxaban—Vomiting—Hydroxyurea—head and neck cancer	0.00173	0.00433	CcSEcCtD
Rivaroxaban—Dyspepsia—Fluorouracil—head and neck cancer	0.00173	0.00431	CcSEcCtD
Rivaroxaban—Rash—Hydroxyurea—head and neck cancer	0.00172	0.00429	CcSEcCtD
Rivaroxaban—Dermatitis—Hydroxyurea—head and neck cancer	0.00172	0.00429	CcSEcCtD
Rivaroxaban—Headache—Hydroxyurea—head and neck cancer	0.00171	0.00426	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00169	0.00423	CcSEcCtD
Rivaroxaban—Back pain—Docetaxel—head and neck cancer	0.00168	0.00419	CcSEcCtD
Rivaroxaban—Pain—Fluorouracil—head and neck cancer	0.00168	0.00419	CcSEcCtD
Rivaroxaban—Muscle spasms—Docetaxel—head and neck cancer	0.00167	0.00417	CcSEcCtD
Rivaroxaban—Nausea—Hydroxyurea—head and neck cancer	0.00162	0.00404	CcSEcCtD
Rivaroxaban—Feeling abnormal—Fluorouracil—head and neck cancer	0.00162	0.00404	CcSEcCtD
Rivaroxaban—Anaemia—Docetaxel—head and neck cancer	0.0016	0.004	CcSEcCtD
Rivaroxaban—Urticaria—Fluorouracil—head and neck cancer	0.00156	0.00389	CcSEcCtD
Rivaroxaban—Syncope—Docetaxel—head and neck cancer	0.00156	0.00389	CcSEcCtD
Rivaroxaban—Loss of consciousness—Docetaxel—head and neck cancer	0.00153	0.00381	CcSEcCtD
Rivaroxaban—Chest pain—Docetaxel—head and neck cancer	0.00148	0.00369	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00147	0.00366	CcSEcCtD
Rivaroxaban—Hypersensitivity—Fluorouracil—head and neck cancer	0.00145	0.00361	CcSEcCtD
Rivaroxaban—Dry mouth—Docetaxel—head and neck cancer	0.00145	0.00361	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Docetaxel—head and neck cancer	0.00142	0.00354	CcSEcCtD
Rivaroxaban—Oedema—Docetaxel—head and neck cancer	0.00142	0.00354	CcSEcCtD
Rivaroxaban—Infection—Docetaxel—head and neck cancer	0.00141	0.00351	CcSEcCtD
Rivaroxaban—Shock—Docetaxel—head and neck cancer	0.00139	0.00348	CcSEcCtD
Rivaroxaban—Nervous system disorder—Docetaxel—head and neck cancer	0.00139	0.00347	CcSEcCtD
Rivaroxaban—Pruritus—Fluorouracil—head and neck cancer	0.00139	0.00347	CcSEcCtD
Rivaroxaban—Tachycardia—Docetaxel—head and neck cancer	0.00138	0.00345	CcSEcCtD
Rivaroxaban—Skin disorder—Docetaxel—head and neck cancer	0.00138	0.00343	CcSEcCtD
Rivaroxaban—Diarrhoea—Fluorouracil—head and neck cancer	0.00134	0.00335	CcSEcCtD
Rivaroxaban—Hypotension—Docetaxel—head and neck cancer	0.00132	0.0033	CcSEcCtD
Rivaroxaban—Dizziness—Fluorouracil—head and neck cancer	0.0013	0.00324	CcSEcCtD
Rivaroxaban—Dyspnoea—Docetaxel—head and neck cancer	0.00126	0.00315	CcSEcCtD
Rivaroxaban—Vomiting—Fluorouracil—head and neck cancer	0.00125	0.00311	CcSEcCtD
Rivaroxaban—Dyspepsia—Docetaxel—head and neck cancer	0.00125	0.00311	CcSEcCtD
Rivaroxaban—Rash—Fluorouracil—head and neck cancer	0.00124	0.00309	CcSEcCtD
Rivaroxaban—Dermatitis—Fluorouracil—head and neck cancer	0.00124	0.00309	CcSEcCtD
Rivaroxaban—Headache—Fluorouracil—head and neck cancer	0.00123	0.00307	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00122	0.00305	CcSEcCtD
Rivaroxaban—Fatigue—Docetaxel—head and neck cancer	0.00122	0.00305	CcSEcCtD
Rivaroxaban—Pain—Docetaxel—head and neck cancer	0.00121	0.00302	CcSEcCtD
Rivaroxaban—Constipation—Docetaxel—head and neck cancer	0.00121	0.00302	CcSEcCtD
Rivaroxaban—Feeling abnormal—Docetaxel—head and neck cancer	0.00117	0.00291	CcSEcCtD
Rivaroxaban—Nausea—Fluorouracil—head and neck cancer	0.00117	0.00291	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00116	0.00289	CcSEcCtD
Rivaroxaban—CYP2J2—Tryptophan metabolism—CYP1A1—head and neck cancer	0.00115	0.0389	CbGpPWpGaD
Rivaroxaban—Abdominal pain—Docetaxel—head and neck cancer	0.00112	0.0028	CcSEcCtD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—GPX1—head and neck cancer	0.00109	0.0368	CbGpPWpGaD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.00108	0.0364	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Docetaxel—head and neck cancer	0.00104	0.0026	CcSEcCtD
Rivaroxaban—Asthenia—Docetaxel—head and neck cancer	0.00102	0.00254	CcSEcCtD
Rivaroxaban—Pruritus—Docetaxel—head and neck cancer	0.001	0.0025	CcSEcCtD
Rivaroxaban—Diarrhoea—Docetaxel—head and neck cancer	0.000969	0.00242	CcSEcCtD
Rivaroxaban—Dizziness—Docetaxel—head and neck cancer	0.000937	0.00234	CcSEcCtD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000931	0.0315	CbGpPWpGaD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000919	0.0311	CbGpPWpGaD
Rivaroxaban—Vomiting—Docetaxel—head and neck cancer	0.000901	0.00225	CcSEcCtD
Rivaroxaban—Rash—Docetaxel—head and neck cancer	0.000893	0.00223	CcSEcCtD
Rivaroxaban—Dermatitis—Docetaxel—head and neck cancer	0.000893	0.00223	CcSEcCtD
Rivaroxaban—Headache—Docetaxel—head and neck cancer	0.000888	0.00222	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—NAT2—head and neck cancer	0.000857	0.029	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—NAT2—head and neck cancer	0.000845	0.0286	CbGpPWpGaD
Rivaroxaban—Nausea—Docetaxel—head and neck cancer	0.000842	0.0021	CcSEcCtD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000755	0.0255	CbGpPWpGaD
Rivaroxaban—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.000734	0.0248	CbGpPWpGaD
Rivaroxaban—CYP3A5—Xenobiotics—CYP1A1—head and neck cancer	0.000646	0.0218	CbGpPWpGaD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000641	0.0217	CbGpPWpGaD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000623	0.0211	CbGpPWpGaD
Rivaroxaban—CYP3A5—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000622	0.021	CbGpPWpGaD
Rivaroxaban—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	0.000569	0.0192	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—GSTM1—head and neck cancer	0.000423	0.0143	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—GSTM1—head and neck cancer	0.000417	0.0141	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—CYP1A1—head and neck cancer	0.000401	0.0136	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000396	0.0134	CbGpPWpGaD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000384	0.013	CbGpPWpGaD
Rivaroxaban—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.000359	0.0121	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—UROD—head and neck cancer	0.000353	0.0119	CbGpPWpGaD
Rivaroxaban—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	0.000345	0.0117	CbGpPWpGaD
Rivaroxaban—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	0.000327	0.0111	CbGpPWpGaD
Rivaroxaban—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.000301	0.0102	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000289	0.00977	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—GRP—head and neck cancer	0.00028	0.00945	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000274	0.00925	CbGpPWpGaD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000268	0.00907	CbGpPWpGaD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000265	0.00895	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—NAT2—head and neck cancer	0.000247	0.00834	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—NAT2—head and neck cancer	0.000243	0.00823	CbGpPWpGaD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000218	0.00736	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.000157	0.0053	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000156	0.00526	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000154	0.00522	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000154	0.00521	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—NAT2—head and neck cancer	0.000146	0.00495	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.000143	0.00482	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—DPYD—head and neck cancer	0.000128	0.00434	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000125	0.00422	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000123	0.00416	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GSTM1—head and neck cancer	0.000122	0.00412	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—YAP1—head and neck cancer	0.000122	0.00412	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSTM1—head and neck cancer	0.00012	0.00406	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CASP8—head and neck cancer	0.000119	0.00401	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP1A1—head and neck cancer	0.000116	0.00391	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.000115	0.00388	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000114	0.00385	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.000113	0.00383	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—UROD—head and neck cancer	0.000102	0.00344	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000101	0.00342	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—IL2—head and neck cancer	9.47e-05	0.0032	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	9.16e-05	0.0031	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL2—head and neck cancer	8.96e-05	0.00303	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	8.79e-05	0.00297	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	8.6e-05	0.00291	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	8.56e-05	0.00289	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—VEGFA—head and neck cancer	8.05e-05	0.00272	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	7.99e-05	0.0027	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—UROD—head and neck cancer	7.67e-05	0.00259	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—MAPK3—head and neck cancer	7.61e-05	0.00257	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—VEGFA—head and neck cancer	7.61e-05	0.00257	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—TYMS—head and neck cancer	7.32e-05	0.00247	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—MAPK1—head and neck cancer	7.24e-05	0.00245	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTM1—head and neck cancer	7.23e-05	0.00245	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GPX1—head and neck cancer	6.93e-05	0.00234	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP1A1—head and neck cancer	6.86e-05	0.00232	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PIK3CA—head and neck cancer	6.29e-05	0.00213	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TP53—head and neck cancer	6.08e-05	0.00206	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	5.85e-05	0.00198	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—HRAS—head and neck cancer	5.82e-05	0.00197	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	5.67e-05	0.00192	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.63e-05	0.0019	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	5.61e-05	0.0019	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	5.59e-05	0.00189	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	5.37e-05	0.00182	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	5.3e-05	0.00179	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—AKT1—head and neck cancer	5.14e-05	0.00174	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	5.02e-05	0.0017	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	4.77e-05	0.00161	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—UROD—head and neck cancer	4.73e-05	0.0016	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	4.31e-05	0.00146	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NAT2—head and neck cancer	4.22e-05	0.00143	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	4.16e-05	0.00141	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTGS2—head and neck cancer	4.08e-05	0.00138	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	3.76e-05	0.00127	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—DPYD—head and neck cancer	3.7e-05	0.00125	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTEN—head and neck cancer	3.56e-05	0.0012	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	3.55e-05	0.0012	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—YAP1—head and neck cancer	3.51e-05	0.00119	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	3.38e-05	0.00114	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	3.38e-05	0.00114	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NAT2—head and neck cancer	3.19e-05	0.00108	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	2.93e-05	0.000992	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	2.84e-05	0.00096	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—DPYD—head and neck cancer	2.79e-05	0.000944	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—YAP1—head and neck cancer	2.65e-05	0.000896	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PIK3CA—head and neck cancer	2.51e-05	0.000848	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	2.4e-05	0.00081	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—TYMS—head and neck cancer	2.11e-05	0.000713	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTM1—head and neck cancer	2.09e-05	0.000705	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—AKT1—head and neck cancer	2.05e-05	0.000693	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GPX1—head and neck cancer	2e-05	0.000675	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP1A1—head and neck cancer	1.98e-05	0.000668	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NAT2—head and neck cancer	1.96e-05	0.000663	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—DPYD—head and neck cancer	1.72e-05	0.000582	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—YAP1—head and neck cancer	1.63e-05	0.000552	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—TYMS—head and neck cancer	1.59e-05	0.000538	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTM1—head and neck cancer	1.57e-05	0.000532	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GPX1—head and neck cancer	1.51e-05	0.000509	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP1A1—head and neck cancer	1.49e-05	0.000504	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTGS2—head and neck cancer	1.18e-05	0.000397	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTEN—head and neck cancer	1.03e-05	0.000347	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TYMS—head and neck cancer	9.81e-06	0.000331	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTM1—head and neck cancer	9.69e-06	0.000328	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GPX1—head and neck cancer	9.28e-06	0.000314	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP1A1—head and neck cancer	9.19e-06	0.000311	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTGS2—head and neck cancer	8.87e-06	0.0003	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTEN—head and neck cancer	7.74e-06	0.000261	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CA—head and neck cancer	7.23e-06	0.000244	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—AKT1—head and neck cancer	5.91e-06	0.0002	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTGS2—head and neck cancer	5.46e-06	0.000185	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CA—head and neck cancer	5.46e-06	0.000184	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTEN—head and neck cancer	4.77e-06	0.000161	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—AKT1—head and neck cancer	4.46e-06	0.000151	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CA—head and neck cancer	3.36e-06	0.000114	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—AKT1—head and neck cancer	2.75e-06	9.28e-05	CbGpPWpGaD
